Weekly Recap: 14 Health Press Releases You Need to See

A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including AI-powered dream reconstruction, veterans' health at the Indy 500 and the first generic version of Tasigna^®.

NEW YORK, May 30, 2025 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help healthcare journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed.

The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that are available for download.

1. Lilly To Expand Its Pain Pipeline With Acquisition of SiteOne Therapeutics 
   "The global burden of chronic pain continues to increase, and an effective non-opioid treatment remains elusive," said Mark Mintun, Lilly group vice president Neuroscience Research and Development. "Lilly is eager to continue the development of STC-004 with the outstanding SiteOne team as part of our efforts to advance novel, addiction-free pain therapies." 
2. INDY 500 Stars Join Forces with ZERO Prostate Cancer to Put Veterans' Health in the Spotlight at Memorial Day Weekend Races 
   In partnership with Juncos Hollinger Racing, ZERO's logo was featured on two cars in the 109th Running of the Indianapolis 500—the world's biggest single-day sporting event—on Sunday, May 25. The message? Veterans are twice as likely to face prostate cancer—and early detection saves lives.
3. Shaklee Continues to Expand Its Innovative Wellness Product Offering Through New Acquisition 
   The acquisition includes Modere's rights to all the trademarks, patents, and formulas for all Modere products including Liquid BioCell^® Collagen and Trim – the two most popular product lines in the Modere portfolio. The acquisition also includes all the manufacturing and testing equipment in Modere's North American manufacturing facilities and all related inventory.
4. Gilgamesh Pharmaceuticals Announces Positive Topline Phase 2a Results for GM-2505 in Major Depressive Disorder (MDD)
   "The clinical response and remission rates highlight the potential for GM-2505 to be a groundbreaking therapy for patients with MDD," said Jonathan Sporn, MD, Founder and CEO of Gilgamesh Pharmaceuticals. "GM-2505's rapid and sustained antidepressant effect fits seamlessly into the existing two-hour in-clinic treatment model."
5. Valeris Launches with a Fully Integrated Vision for Life Sciences Companies 
   By uniting capabilities that deliver value throughout the commercialization process – data and strategic insights, patient support services, and healthcare provider engagement tools, Valeris represents a bold commitment to a better patient experience by streamlining access, reducing barriers, and supporting adherence.
6. UniXell Biotechnology announces the first patient dosed with UX-DA001, an investigational autologous iPSC based cell therapy for the treatment of Parkinson's Disease, in Its Phase 1 study
   The first recipient of UniXell's autologous stem cell-derived drug, UX-DA001, shared, "after receiving the stem cell treatment, I experienced a remarkable improvement in my sleep quality. I fall asleep quickly and notice gradual progress every day. Although recovery takes time, the 'day by day improvement' fills me with hope for the future."
7. The Sandlot Star Patrick Renna Teams Up with Dramamine^® to Revisit an Iconic Scene - This Time, Puke Free
   The Advanced Herbals™ supplement line by the makers of Dramamine^® is giving Americans the chance to win a vacation do-over, this time with Ginger Chews as a solution for unwelcome nausea.
8. Coalesce Capital Acquires Leading Healthcare IT and Business Solutions Provider DAS Health 
   DAS Health provides a comprehensive suite of IT, cybersecurity, revenue cycle management, and business solutions to thousands of healthcare organizations across North America, streamlining workflows, increasing productivity, and improving patient care. Coalesce will support DAS Health's growth by investing in technology, talent, and strategic acquisitions, further strengthening the company's ability to deliver value to healthcare organizations.
9. Celltrion's YUFLYMA^® (adalimumab-aaty) receives FDA interchangeability designation for all Its approved dosage forms and strengths 
   "This full interchangeability designation comes at a pivotal time as Celltrion continues to lead in the evolving biosimilar landscape," said Thomas Nusbickel, Chief Commercial Officer at Celltrion USA. "YUFLYMA – a high-concentration, citrate-free adalimumab biosimilar now fully interchangeable with Humira – reflects our long-standing commitment to delivering high-quality, accessible treatment options."
10. Pillar Biosciences Raises $34.5M in Funding
    Proceeds from this financing will be leveraged to advance Pillar's commercial activities including headcount and infrastructure to support biopharma partnerships and expand adoption of its distributable clinical testing kits.
11. START and OneOncology Partner To Expand Access to Early Phase Oncology Trials 
    This strategic partnership directly addresses the critical need to expand access to innovative cancer therapies in community practices, where the majority of cancer patients receive care but have historically had access to fewer than 20% of early phase clinical trials.
12. Apotex launches nilotinib capsules, the first generic version of Tasigna^® in the United States, with 180 days of exclusivity 
    "By offering the first generic version of this important leukemia treatment, we improve access and outcomes for both adult and pediatric patients facing this serious disease," said Christine Baeder, President, Apotex USA.
13. O'Shaughnessy Ventures Backs AI-Powered Dream Reconstruction 
    Ninon Lizé Masclef will use the fellowship to develop a prototype brain-computer interface that uses artificial intelligence to convert raw brain-wave data into immersive, 3D reconstructions of dreams. She will present her findings at a scientific conference and use the work as the foundation for a broader initiative to decode the subconscious through neural interfaces.
14. New Strategic Partnership Between ConnectureDRX and EvolveNXT Unifies Agent Onboarding, Enrollment, and Commissions 
    This collaboration brings together two industry-leading platforms to create a seamless, end-to-end experience for health plans, agencies, and their producers, streamlining everything from onboarding to enrollments to commissions. It reflects both companies' commitment to exceptional client experience and to solving Medicare's complex challenges with innovative technology that empowers agents and simplifies compliance.

For more news like this, check out all of the latest health-related releases from PR Newswire.

Do you have a health press release to distribute? Sign up with PR Newswire to share your story with the audiences who matter most.

Helping Journalists Stay Up to Date on Industry News

These are just a few of the recent press releases that consumers and the media should know about. To be notified of releases relevant to their coverage area, journalists can set up a custom newsfeed with PR Newswire for Journalists.

Once they're signed up, reporters, bloggers, and freelancers have access to the following free features:

• Customization: Users can create customized newsfeeds that will deliver relevant news right to their inbox. Newsfeed results can be targeted by keywords, industry, subject, geography, and more.
• Photos and Videos: Thousands of multimedia assets are available to download and include in a journalist or blogger's next story.
• Subject Matter Experts: Journalists will have access to ProfNet, a database of industry experts to connect with as sources or for quotes in their articles.
• Related Resources: Our journalist- and blogger-focused blog, Beyond Bylines, features regular media news roundups, writing tips, upcoming events, and more.

About PR Newswire

PR Newswire is the industry's leading press release distribution partner with an unparalleled global reach of more than 440,000 newsrooms, websites, direct feeds, journalists and influencers and is available in more than 170 countries and 40 languages. From our award-winning Content Services offerings, integrated media newsroom and microsite products, Investor Relations suite of services, paid placement and social sharing tools, PR Newswire has a comprehensive catalog of solutions to solve the modern-day challenges PR and communications teams face. For 70 years, PR Newswire has been the preferred destination for brands to share their most important news stories across the world.

For questions, contact the team at [email protected].

SOURCE PR Newswire